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CASE REPORT
Large Superficial Basal Cell Carcinoma Arising in 
the Scalp
Min Soo Jang, M.D., Jae Woo Baek, M.D., Jong Bin Park, M.D., Dong Young Kang, M.D., 
Jin Seuk Kang, M.D., Kee Suck Suh, M.D., Sang Tae Kim, M.D.
Department of Dermatology, Kosin University College of Medicine, Busan, Korea 
Superficial basal cell carcinoma (sBCC), a rare sub-type of 
basal cell carcinoma, can frequently occur in younger 
patients. This cancer type preferentially develops on the 
trunk. However, other subtypes of BCC can occur in the head 
and neck, probably secondary to sunlight exposure. 
Especially, sBCC on the scalp has been rarely-reported, 
accounting for 0.7∼0.8% of all sBCC cases. We report a case 
of 71-year-old female with a large sBCC of the scalp, an 
unusual site of sBCC. (Ann Dermatol 23(S1) S96∼S99, 2011)
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INTRODUCTION
The incidence of basal cell carcinoma (BCC) has increased 
because of life style changes that include more outdoor 
activities
1-4. Since there are several histological sub-types 
of BCC, accurate diagnosis is essential for selection of the 
proper treatment
5. Superficial BCC (sBCC) is one of the 
sub-types that can preferentially develop on the trunk or 
limb, while the other subtypes of BCC are mainly found 
on the head and neck
2-4,6,7. Since sBCC can be found on 
parts of the body that receive only rare sun exposure, it is 
suggested that sBCC should be considered a rare and 
separate type of BCC. We report a case involving a large 
sBCC found on the scalp, a rare location for sBCC.
CASE REPORT
A 71-year-old female presented with a violaceous to 
blackish crusted plaque, approximately 6.5×6.5 cm, with 
slightly raised irregular borders on the parietal area of her 
scalp (Fig. 1A). The lesion, which had developed 4 years 
earlier, had begun growing rapidly for the previous 4 
months prior to the patient’s visit to our department. Skin 
biopsies of the lesion showed the typical histopathological 
features of sBCC with budding and peripherally palisading 
basaloid tumor cells in the epidermis (Fig. 2A). There was 
also partial stromal retraction between the tumor nest and 
the dermis. Although surgical excision is the usual treat-
ment, this approach was not considered to be the best 
choice in this case due to the large size of the lesion and 
subsequent cosmetic problems with closure. Instead, the 
patient was instructed to apply 5% imiquimod cream once 
a day, at least five times a week for 12 weeks. The patient 
was examined every 2 weeks. Skin burning, erythema, 
and crust were observed as local skin reactions, but the 
level of this skin reaction was relatively less than expected 
(Fig. 1B). After the 12 weeks of topical imiquimod, the 
follow-up biopsy specimen showed remarkable regression 
of tumor cells, although they were not completely 
dissipated (Fig. 2B). After continued application of 
imiquimod for an additional 4 weeks, the biopsy showed 
remission of the tumor cells (Fig. 2C). Despite the 
re-treatment, three or four pin-point blackish macules 
were observed over the next 4 months. Targeted biopsy 
was performed on three suspicious lesions that showed 
remnant tumor cells around the excised tissue (Fig. 1C). 
Therefore, two sessions (1 week apart) of topical photody-Large Superficial Basal Cell Carcinoma Arising in the Scalp
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Fig. 1. (A) Localized mild tender 
violaceous to blackish 6.5×6.5 cm-
sized plaque with a slightly raised 
and irregular border. (B) Clinical 
improvement was noted after 12 
weeks of imiquimod treatment. (C) 
Targeted biopsy (green circle) per-
formed on the blackish area after 
application of imiquimod for 16 
weeks. (D) Three months after the 
termination of additional photody-
namic therapy with methyl 5-amino-
levulinic acid, the lesion showed 
clinically complete remission.
Fig. 2. (A) Initial biopsy specimen prior to imiquimod application, showing irregular proliferation of tumor tissue with palisading 
peripheral cells (H&E, ×100). (B) Marked reduction of tumor tissue after 12 weeks of imiquimod treatment (H&E, ×40). (C) Targeted
biopsy specimen after 16 weeks of treatment showing excised tumor tissue with a free margin (H&E, ×40). (D) No tumor cells were
found 3 months after the photodynamic therapy with methyl 5-aminolevulinic acid (H&E, ×100). MS Jang, et al
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namic therapy (PDT) with methyl 5-aminolevulinic acid 
(Metvix
Ⓡ, Galderma, Oslo, Norway) and red light (Aktilite 
lamp
Ⓡ, PhotoCure ASA, Oslo, Norway) were recommend-
ed to the patient, since the lesion was studded with sBCC. 
No sign of any clinically suspicious blackish areas (Fig. 
1D) or histological tumor cells were found 3 months after 
the methyl 5-aminolevulinic acid-PDT application (Fig. 
2D), and no recurrence was noted during the 2-year 
follow-up.
DISCUSSION
BCC is the most common cutaneous malignancy in 
Caucasians. Recently, the incidence of BCC has been 
increasing among Asians, and the overall number of BCC 
cases has been growing rapidly
1,8,9. The clinical charac-
teristics of BCC appear commonly on the head and neck 
areas, and the most common subtype of BCC is the 
histopathologically distinct nodular type
1,6-8. sBCC is 
primarily developed on the trunk, in contrast to the other 
subtypes
2-4,7,9. The different locations between sBCC and 
the other subtypes of BCC provides indirect favorable 
evidence for the hypothesis that the tumor biology and 
histological patterns of BCC subtypes may differ according 
to their anatomic locations
2-4,6. It has been suggested that 
sBCC is a separate group within the clinical entity of BCC, 
of which intermittent sun exposure may be an important 
etiology
2-4,6,7. In present case, the lesion developed on the 
scalp, which is often a sun-covered area, but lesional scalp 
may not be a fully sun-cover area because of scanty hair 
due to both pilofollicular recess itself and senile change. 
McCormack et al.
2 proposed that there are some 
similarities between sBCC and superficial spreading 
melanoma in terms of the truncal predominance and 
occurrence in younger patients. 
sBCC has been reported extremely rare in the scalp 
accounting for 0.7∼0.8% of all sBCC
6. Recently, however, 
some studies reported an increased incidence of sBCC, 
especially on the head and neck including the scalp
10,11. 
Arits et al.
10 reported a proportional increase in sBCC from 
17.6% to 30.7%. They also reported that 14.3% of all 
sBCC was located in the head and neck region. Because 
of increasing tendency in sBCC on the head and neck, 
careful attention is necessary when examining any partial 
crust or erythematous plaque on the scalp. This thorough-
ness is necessary to distinguish it from other clinically 
mimicking skin diseases such as seborrheic dermatitis
12 
and Bowen disease
13. 
Treatment of sBCC can be divided into surgical and 
non-surgical treatment. Although the surgical approach 
remains the first-line therapy for BCC, it is not easy due to 
multifocal skip lesions histopathologically, and wide 
lesions
14. Non-surgical treatments include topical chemo-
therapeutics, biological-immune-response modifiers, reti-
noids, and photodynamic therapy, which can be used 
particularly in patients with sBCC and are available for 
situations in which the invasive treatment is not appr-
opriate
5,13,15. In this case, the patient declined any surgical 
therapy, even though that was the treatment of choice. 
Since the lesion developed on the scalp, we considered 
non-surgical treatment a better cosmetic and functional 
result. The primary treatment was topical application of 
imiquimod, which acts as an immune response modifier. 
There are a variety of histological clearances depending 
on the tumor location during imiquimod treatment
15. In 
this case, the sBCC appeared to be in clinical remission 
after 16 weeks of imiquimod treatment. However, a few 
scattered tumor cells were found on the subsequent 
biopsy. Although skin appendages on the scalp could be 
better for absorption of lipid or water soluble substances, 
the thicker scalp skin layer than the frequent anatomic 
region of sBCC may result in milder local skin reactions, 
which leads to insufficient histological clearance of tumor 
cells
5,15. It was also postulated that the limited efficacy of 
imiquimod could be due to uneven topical application, 
compromised by scalp hair. We experienced complete 
clinical and histological remission after the application of 
PDT with methyl 5-aminolevulinic acid twice daily with a 
1-week interval. 
In conclusion, owing to recently increasing tendency of 
sBCC in head and neck area, dermatologists should 
consider this as one of differential diagnosis of a wide 
scaly lesion on this area.
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